Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients

被引：0

作者：

Gutierrez, Lourdes ^{[1
]}

Mendez, Santiago ^{[2
]}

Mitjavila, Mercedes ^{[3
]}

Llop, Elba ^{[4
]}

Salas, Clara ^{[5
]}

Ruiz-Casado, Ana ^{[1
]}

机构：

[1] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain

[2] Hosp Univ Puerta Hierro Majadahonda, Dept Vasc Radiol, Madrid, Spain

[3] Hosp Univ Puerta Hierro Majadahonda, Dept Nucl Med, Madrid, Spain

[4] Hosp Univ Puerta Hierro Majadahonda, Dept Gastroenterol, Madrid, Spain

[5] Hosp Univ Puerta Hierro Majadahonda, Dept Pathol, Madrid, Spain

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2019年 / 15卷 / 01期

关键词：

Late toxicity; liver metastases; portal hypertension; regenerative nodular hyperplasia; SIRT; OXALIPLATIN-BASED CHEMOTHERAPY; LIVER METASTASES; RADIOEMBOLIZATION; MICROSPHERES; RADIOTHERAPY; MULTICENTER; SAFETY;

D O I：

10.4103/jcrt.JCRT_13998_16

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Selective internal radiation therapy (SIRT) is increasingly used in different scenarios. Although portal hypertension (PHT) has been described as a nonclinically relevant finding after SIRT, its real incidence could have been neglected due to the nature of the diseases for which SIRT is indicated. Case Reports: Here we report three cases with clinically relevant late PHT after treatments including SIRT and oxaliplatin among others. Discussion: The sequential use of oxaliplatin and SIRT in patients with colorectal cancer metastases could have additive effects on the liver.

引用

页码：42 / 47

页数：6

共 9 条

[1] Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer
Shankaran, Veena
Mummy, David
Koepl, Lisel
Blough, David
Yim, Yeun Mi
Yu, Elaine
Ramsey, Scott
CLINICAL COLORECTAL CANCER, 2013, 12 (03) : 204 - +
[2] Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
Unseld, Matthias
Drimmel, Magdalena
Siebenhuner, Alexander
Gleiss, Andreas
Bianconi, Daniela
Kieler, Markus
Scheithaueer, Werner
Winder, Thomas
Prager, Gerald W.
CLINICAL COLORECTAL CANCER, 2018, 17 (04) : 274 - 279
[3] Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
Ge, Pu
Han, Chunyan
Reyila, Abudurousuli
Liu, Diyue
Hong, Wenying
Liu, Jiaxin
Zhang, Jinzi
Han, Xiao
Li, Xialei
Huang, Mengjie
Fan, Siyuan
Kaierdebieke, Ayidana
Wu, Xiaoyu
Huang, Xiaolu
Guo, Weirui
Liu, Siyu
Bian, Ying
MEDICINE, 2023, 102 (35) : E34793
[4] A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions
Su, Hai-chuan
Min, Jie
Song, Yang
Liu, Li-li
Liu, Lin-na
Zhang, He-long
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 167 - 177
[5] A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions
Hai-chuan Su
Jie Min
Yang Song
Li-li Liu
Lin-na Liu
He-long Zhang
Cancer Chemotherapy and Pharmacology, 2023, 91 : 167 - 177
[6] Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Roubaud, Guilhem
Oezgueroglu, Mustafa
Penel, Nicolas
Matsubara, Nobuaki
Mehra, Niven
Kolinsky, Michael P.
Procopio, Giuseppe
Feyerabend, Susan
Joung, Jae Young
Gravis, Gwenaelle
Nishimura, Kazuo
Gedye, Craig
Padua, Charles
Shore, Neal
Thiery-Vuillemin, Antoine
Saad, Fred
van Alphen, Robbert
Carducci, Michael A.
Desai, Chintu
Brickel, Neil
Poehlein, Christian
Del Rosario, Paula
Fizazi, Karim
EUROPEAN JOURNAL OF CANCER, 2022, 170 : 73 - 84
[7] Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
Nakajima, Hiromichi
Fukuoka, Shota
Masuishi, Toshiki
Takashima, Atsuo
Kumekawa, Yosuke
Kajiwara, Takeshi
Yamazaki, Kentaro
Negoro, Yuji
Komoda, Masato
Makiyama, Akitaka
Denda, Tadamichi
Hatachi, Yukimasa
Suto, Takeshi
Sugimoto, Naotoshi
Enomoto, Masanobu
Ishikawa, Toshiaki
Kashiwada, Tomomi
Ando, Koji
Yuki, Satoshi
Okuyama, Hiroyuki
Kusaba, Hitoshi
Sakai, Daisuke
Okamoto, Koichi
Tamura, Takao
Yamashita, Kimihiro
Gosho, Masahiko
Moriwaki, Toshikazu
FRONTIERS IN ONCOLOGY, 2021, 11
[8] FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer
Dutton, Susan J.
Kenealy, Nicola
Love, Sharon B.
Wasan, Harpreet S.
Sharma, Ricky A.
BMC CANCER, 2014, 14
[9] FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer
Susan J Dutton
Nicola Kenealy
Sharon B Love
Harpreet S Wasan
Ricky A Sharma
BMC Cancer, 14

← 1 →